Protara Therapeutics, Inc. — Director's Dealing 2020

Sep 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-09-22

Reporting Person: Davis Blaine (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-22	Common Stock	P	1481	$16.906	Acquired	1481	Direct

Footnotes

F1: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.885 to $16.935, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.